Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 64.7%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,800 shares, a growth of 64.7% from the March 31st total of 1,700 shares. Based on an average daily trading volume, of 5,800 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the company’s stock are sold short.

Xenetic Biosciences Trading Up 8.3 %

Shares of XBIO stock opened at $4.09 on Friday. Xenetic Biosciences has a 1 year low of $2.55 and a 1 year high of $5.97. The firm’s fifty day moving average price is $4.09 and its two-hundred day moving average price is $3.72. The firm has a market capitalization of $6.30 million, a P/E ratio of -1.49 and a beta of 2.60.

Xenetic Biosciences (NASDAQ:XBIO) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.10. Xenetic Biosciences had a negative net margin of 162.84% and a negative return on equity of 36.43%. The firm had revenue of $0.67 million for the quarter, compared to analyst estimates of $0.68 million. As a group, equities research analysts forecast that Xenetic Biosciences will post -3.43 EPS for the current fiscal year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.